GSK's leukemia drug Arzerra wins FDA approval for expanded use

04/18/2014 | Medscape (free registration)

GlaxoSmithKline obtained the FDA's full approval to market Arzerra injection, or ofatumumab, in combination with chlorambucil, for patients with previously untreated chronic lymphocytic leukemia who can't take fludarabine-based drugs. The approval was based on data from a multicenter trial that showed improvements in progression-free survival among patients who took the combination therapy. Arzerra is already cleared for treatment of CLL patients who don't respond to alemtuzumab and fludarabine.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ